Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 80

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 80
---
.

If NewGenIvf loses its relationship with one or more key pharmaceutical manufacturers, its business and results of operations could be adversely affected.

NewGenIvf maintains contractual
relationships with select pharmaceutical manufacturers in Thailand, Cambodia and Kyrgyzstan. The consolidation of pharmaceutical manufacturers,
the shortages of drugs provided by such manufacturers, the termination or material alteration of its contractual relationships, or its
failure to renew such contracts could have a material adverse effect on its business and results of operations. Adoption of new laws,
rules or regulations or changes in, or new interpretations of, existing laws, rules or regulations, relating to any of these programs
could materially adversely affect its business and results of operations.

NewGenIvf has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.

NewGenIvf has entered into
a number of transactions with related parties. NewGenIvf may in the future enter into additional transactions with its related parties.
Interests of these related parties may not necessarily be aligned with NewGenIvf’s or The Company’s interests and the interests
of its other shareholders. For example, conflicts of interest may arise in connection with decisions regarding the transaction arrangements
which may be less favorable to NewGenIvf than similar arrangements negotiated with unaffiliated third parties. Conflicts of interest may
also arise in connection with the exercise of contractual remedies, such as the treatment of events of default. As a result, those related
party transactions, individually or in the aggregate, may have an adverse effect on NewGenIvf’s business and results of operations.

NewGenIvf may be subject to claims and allegations relating to intellectual property and other causes.

NewGenIvf may from time
to time receive claims that NewGenIvf infringes on the intellectual property rights of others. Moreover, NewGenIvf may be subject to
claims by third parties who maintain that NewGenIvf’s service providers’ technology infringes third-party’s
intellectual property rights. If NewGenIvf fails to successfully defend against such claim or does not prevail in such litigation,
it could be required to modify, redesign or cease operating, pay monetary amounts as damages or enter into royalty or licensing
arrangements with the valid intellectual property holders. Any royalty or licensing arrangements that NewGenIvf may seek in such
circumstances may not be available to it on commercially reasonable terms or at all. Also, if NewGenIvf acquires